Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Thelper
Oslo, Norway
A
1-10 Employees
2019
Key takeaway
Thelper AS is focused on developing innovative cancer therapies through its discovery of novel viral targets that are highly expressed in tumors but absent in healthy tissue. This approach aims to create potent immunotherapies that could transform treatment for solid tumor patients, potentially reducing toxicity by sparing healthy cells.
Reference
Core business
Thelper AS
ClexBio
Oslo, Norway
A
1-10 Employees
2020
Key takeaway
ClexBio is a pre-clinical stage regenerative medicine company focused on innovative tissue engineering solutions. Their proprietary technology platform enables scalable and high-throughput tissue generation, which could be relevant for advancements in in vivo gene therapy applications.
Reference
Core business
ClexBio | Engineering Human Tissue Transplants
ClexBio is a biotech company creating innovative solutions for tissue engineering and single-cell techniques using advanced microfluidics and the proprietary CLEX hydrogel technology.
Bioinvent International AB
Rana, Norway
A
1-10 Employees
2018
Key takeaway
BioInvent is a clinical-stage company focused on developing innovative antibody-based immunotherapies for cancer. Their unique pipeline targets both hematological cancers and solid tumors, highlighting their commitment to advancing treatment options in the expanding immunotherapy market.
Reference
Product
n-CoDeR | BioInvent
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
EXACT THERAPEUTICS AS
Oslo, Norway
A
1-10 Employees
2012
Key takeaway
EXACT Therapeutics AS is developing a novel ultrasound-mediated technology platform, Acoustic Cluster Therapy (ACT®), which significantly enhances the delivery of therapeutic agents, including those used in gene therapy. Their approach focuses on precise and targeted delivery, improving the clinical utility of treatments for various conditions, such as cancer and neurological disorders.
Reference
Product
Technology — EXACT THERAPEUTICS
Glycanova AS
Fredrikstad, Norway
A
1-10 Employees
2009
Key takeaway
GlycaNova is a Norwegian biotechnology company that is developing beta-glucans derived from medicinal mushrooms to modulate the immune system, with a focus on cancer treatment. They are currently conducting a clinical trial where late-stage colorectal cancer patients receive their proprietary beta-glucan, LentinexHP, alongside chemotherapy.
Reference
Core business
GlycaNova
GlycaNova develops, manufactures and markets nutraceuticals and active pharmaceutical ingredients from Basidiomycetes using patented fermentation and separation technology.
iNANOD AS
Oslo, Norway
A
1-10 Employees
-
Key takeaway
iNANOD is a biotech company focused on enhancing cancer treatment through nanotechnology, which allows for more targeted and efficient drug delivery. Their innovative approach aims to improve therapeutic outcomes for patients.
Reference
Core business
INANOD - CANCER DRUG DEVELOPMENT
iNANOD AS is a newly established bio-tech company in Oslo, Norway. iNANOD utilizes nanotechnology to improve drug delivery within oncology, allowing for more targeted delivery of cancer medicines.
Genetic Analysis
Oslo, Norway
A
11-50 Employees
2008
Key takeaway
Genetic Analysis AS is a pioneering diagnostic company with expertise in the human microbiome field, known for developing innovative testing solutions like the GA-map® Dysbiosis Test Lx for diagnosing dysbiosis in IBS and IBD patients. Their commitment to research and development positions them as leaders in delivering advanced diagnostic tools.
Reference
Core business
About Genetic Analysis AS - Genetic Analysis
PubGene
Oslo, Norway
A
11-50 Employees
2001
Key takeaway
PubGene AS focuses on developing bioinformatics solutions that enhance the understanding of personalized medicine, which is relevant to in vivo gene therapy. Their innovative Coremine platform organizes information related to genes and medical concepts, potentially facilitating advancements in gene therapy research.
Reference
Product
Products
MIM PHARMA
Oslo, Norway
A
11-50 Employees
2013
Key takeaway
MIM Pharma is a science-driven organization focused on improving human health through innovative medical solutions. Their research team has developed a natural plant-based antiviral and immune-enhancing solution, which may have implications for gene therapy approaches to combat viruses like COVID-19 and influenza.
Reference
Core business
MIM PHARMA
InVivo Bionics
Oslo, Norway
A
1-10 Employees
2018
Key takeaway
The InVivo Bionics team, based in Oslo, Norway, is dedicated to innovating in the urologic field, with expertise in regulatory matters and market access strategies. Their focus on minimally invasive surgical procedures, led by Dr. Lennart Wagrell, positions them as key players in advancing medical technologies.
Reference
Core business
About Us — InVivo Bionics
Technologies which have been searched by others and may be interesting for you:
When exploring the In Vivo Gene Therapy industry in Norway, several key considerations emerge. Regulatory frameworks are crucial, as Norway adheres to the European Medicines Agency (EMA) guidelines, which govern clinical trials and product approvals. Understanding these regulations can significantly affect the timeline and costs associated with bringing a therapy to market. The industry faces challenges such as the high costs of research and development, and the complexity of delivering therapies effectively within the body. However, opportunities abound, especially with Norway's strong emphasis on biotechnology and healthcare innovation, supported by government funding and initiatives. The competitive landscape is marked by both established companies and startups, with a focus on collaboration between academia and industry to advance research. It is essential to assess the existing players and their technological advancements to identify potential partnerships or investment opportunities. Additionally, global market relevance is significant, as Norway is becoming a hub for biotechnology in Europe, attracting international interest. Environmental concerns also play a role, particularly regarding the sustainability of production processes and the ethical implications of gene editing technologies. By considering these factors, individuals can gain valuable insights into the dynamics of the In Vivo Gene Therapy sector in Norway.
Some interesting numbers and facts about your company results for In Vivo Gene Therapy
| Country with most fitting companies | Norway |
| Amount of fitting manufacturers | 53 |
| Amount of suitable service providers | 22 |
| Average amount of employees | 1-10 |
| Oldest suiting company | 2001 |
| Youngest suiting company | 2020 |
Some interesting questions that has been asked about the results you have just received for In Vivo Gene Therapy
What are related technologies to In Vivo Gene Therapy?
Based on our calculations related technologies to In Vivo Gene Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on In Vivo Gene Therapy?
The most represented industries which are working in In Vivo Gene Therapy are Biotechnology, Other, Medical, IT, Software and Services, Healthcare
How does ensun find these In Vivo Gene Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.